Alizé Pharma: positive results from its Phase II clinical trial in Prader-Willi Syndrome

Graphtys_actu
Graftys announces regulatory clearance in Australia and in Canada
26 April 2016
Orega_actu
OREGA presents its first-in-class CD39 checkpoint inhibitor at the AACR meeting
19 April 2016

Alizé Pharma: positive results from its Phase II clinical trial in Prader-Willi Syndrome

AlizeePharma_actu

The study was aimed at evaluating the safety, tolerability and efficacy of AZP-531 in patients with Prader-Willi Syndrome.